NCT01398267View on ClinicalTrials.gov

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

aleglitazar

150 mcg orally daily, 4 weeks (Day 15 to Day 43)

DRUG

lisinopril

20 mg orally daily, 6 weeks (Day 1 to Day 43)

DRUG

placebo

aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)

Trial Locations (4)

68154

Omaha

75247

Dallas

78209

San Antonio

91911

Chula Vista

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01398267 - A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril | Biotech Hunter | Biotech Hunter